Variation in the genes for thiamine transporters is not a risk
factor for diabetes-related morbidity and mortality

a 2013

Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality

KURICOVÁ, Katarína, Veronika DVOŘÁKOVÁ, Lukáš PÁCAL, Zuzana MARČANOVÁ, Jan SVOJANOVSKÝ et. al.

Základní údaje

Originální název

Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality

Název česky

Variabilita v genech pro tiaminove transportery nejsou rizikové faktory pre diabetickú morbiditu a mortalitu.

Název anglicky

Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality

Autoři

KURICOVÁ, Katarína, Veronika DVOŘÁKOVÁ, Lukáš PÁCAL, Zuzana MARČANOVÁ, Jan SVOJANOVSKÝ, Darja KRUSOVÁ, Jindřich OLŠOVSKÝ, Jana BĚLOBRÁDKOVÁ, Jitka ŘEHOŘOVÁ a Kateřina KAŇKOVÁ

Vydání

Diabetes – a threat to mankind, 2013, 2013

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Změněno: 15. 8. 2013 11:14, Mgr. Katarína Chalásová, Ph.D.

Anotace

V originále

Pentose phosphate pathway (PPP) belongs to the potential targets for the treatment of diabetic microvascular complications. Activation of transketolase (TKT), the key enzyme of non-oxidative branch of PPP, using thiamine supplementation prevents development and progression of diabetic nephropathy in animal model of diabetes. Thiamine which serves as a cofactor for TKT is delivered to the cell via specific thiamine transporters 1 (THTR 1 encoded by the gene SLC19A2) and 2 (THTR 2 encoded by SLC19A3). Plasma thiamine levels in diabetics are decreased due to increased thiamine renal clearance. We have recently demonstrated rise of plasma thiamine in subjects with decreased renal function, however, we did not show parallel increase of intracellular active cofactor [Pácal et al. Nephrol Dial Transplant 2011]. Therefore we propose that major abnormalities in thiamine metabolism most likely take place on the level of thiamine transport into the cell. SNPs in the genes for the thiamine transporters may potentially affect activity of thiamine transport and thus contribute to the progression of DN. The aim of our study was to analyze relationship between genetic variability in SLC19A2 and SLC19A3 loci and diabetes-related morbidity and mortality.

Návaznosti

NT13198, projekt VaV

Název: Pentózový cyklus jako potenciální nový terapeutický cíl v prevenci diabetických komplikací

Investor: Ministerstvo zdravotnictví ČR, Pentózový cyklus jako potenciální nový terapeutický cíl v prevenci diabetických komplikací

Citovat

KURICOVÁ, Katarína, Veronika DVOŘÁKOVÁ, Lukáš PÁCAL, Zuzana MARČANOVÁ, Jan SVOJANOVSKÝ, Darja KRUSOVÁ, Jindřich OLŠOVSKÝ, Jana BĚLOBRÁDKOVÁ, Jitka ŘEHOŘOVÁ a Kateřina KAŇKOVÁ. Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality. In Diabetes – a threat to mankind, 2013. 2013.

@proceedings{1119415,
   author = {Kuricová, Katarína and Dvořáková, Veronika and Pácal, Lukáš and Marčanová, Zuzana and Svojanovský, Jan and Krusová, Darja and Olšovský, Jindřich and Bělobrádková, Jana and Řehořová, Jitka and Kaňková, Kateřina},
   booktitle = {Diabetes – a threat to mankind, 2013},
   title = {Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality},
   year = {2013}
}

TY  - CONF
ID  - 1119415
AU  - Kuricová, Katarína - Dvořáková, Veronika - Pácal, Lukáš - Marčanová, Zuzana - Svojanovský, Jan - Krusová, Darja - Olšovský, Jindřich - Bělobrádková, Jana - Řehořová, Jitka - Kaňková, Kateřina
PY  - 2013
TI  - Variation in the genes for thiamine transporters is not a risk factor for diabetes-related morbidity and mortality
N2  - Pentose phosphate pathway (PPP) belongs to the potential targets for the treatment of diabetic microvascular complications. Activation of transketolase (TKT), the key enzyme of non-oxidative branch of PPP, using thiamine supplementation prevents development and progression of diabetic nephropathy in animal model of diabetes. Thiamine which serves as a cofactor for TKT is delivered to the cell via specific thiamine transporters 1 (THTR 1 encoded by the gene SLC19A2) and 2 (THTR 2 encoded by SLC19A3). Plasma thiamine levels in diabetics are decreased due to increased thiamine renal clearance. We have recently demonstrated rise of plasma thiamine in subjects with decreased renal function, however, we did not show parallel increase of intracellular active cofactor [Pácal et al. Nephrol Dial Transplant 2011]. Therefore we propose that major abnormalities in thiamine metabolism most likely take place on the level of thiamine transport into the cell. SNPs in the genes for the thiamine transporters may potentially affect activity of thiamine transport and thus contribute to the progression of DN. The aim of our study was to analyze relationship between genetic variability in SLC19A2 and SLC19A3 loci and diabetes-related morbidity and mortality.
ER  -

Podrobný výpis o publikaci